Head and Neck Squamous Cell Carcinoma (HNSCC) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Merck, Eli Lilly, Bristol‑Myers Squibb, Sanofi-Aventis, Sinocelltech

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Merck, Eli Lilly, Bristol‑Myers Squibb, Sanofi-Aventis, Sinocelltech
Delveinsight Business Research LLP
As per DelveInsight, the Head and Neck Squamous Cell Carcinoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Head and Neck Squamous Cell Carcinoma, the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and the launch of new therapies in the market.

DelveInsight’s “Head and Neck Squamous Cell Carcinoma (HNSCC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Head and Neck Squamous Cell Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Head and Neck Squamous Cell Carcinoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Head and Neck Squamous Cell Carcinoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Head and Neck Squamous Cell Carcinoma (HNSCC): An Overview

Head and neck cancer is a term used to define cancer that develops in the mouth (oral cavity), throat, nose, salivary glands, oral cancers, or other areas of the head and neck. Most of these are classified as squamous cases which cover 90% of the disease area.

Most HNSCCs arise in the hypopharynx, larynx, trachea, oral cavity, and oropharynx. The majority of laryngeal SCCs originate from the supraglottic and glottic regions. Tracheal SCCs are rare compared to laryngeal ones. The most common oropharyngeal site of involvement is the base of the tongue. Within the oral cavity, most tumors arise from the floor of the mouth, the ventrolateral tongue, or the soft palate complex.

The TNM staging system of the AJCC maintains uniformity in the staging of head and neck tumors which varies with the anatomic location of the primary tumor. Most patients with head and neck cancer have stage III or IV disease at diagnosis and a few patients present with the early stage disease.

The causes of head and neck cancers are not fully understood. There are certain risk factors that increase the risk of developing the disease such as smoking tobacco, consumption of alcohol, and exposure to the human papillomavirus (HPV) which contributes to the development of at least 90% of squamous cell carcinoma of the head and neck. At least 12% of pharyngeal cancer, 3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection.

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Key Facts

  • According to the World Health Organization (2014), the annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year. Male to female ratio ranges from 2:1 to 4:1. About 90% of all head and neck cancers are squamous cell carcinomas (HNSCC).

  • SCC is the most frequent malignant tumor of the head and neck region. HNSCC represents the sixth leading cancer by incidence and there are 500,000 new cases a year worldwide (Kamangar et al., 2006).

  • As per the American Dental Association (2020), Squamous cell carcinoma (SCC) is the most common malignancy in the oral cavity (OC) and oropharynx (OP), accounting for 90% of cancers of the head and neck. OC and OP cancers account for 2.9% of all cancers diagnosed in the U.S. and 1.6% of all cancer Deaths. 

  • According to the National Institutes of Health (2020),  Head and neck cancers account for approximately 4% of all cancers in the United States. These cancers are more than twice as common among men as they are among women. Head and neck cancers are also diagnosed more often among people over age 50 than they are among younger people.

Head and Neck Squamous Cell Carcinoma (HNSCC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Head and Neck Squamous Cell Carcinoma pipeline therapies. It also thoroughly assesses the Head and Neck Squamous Cell Carcinoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Head and Neck Squamous Cell Carcinoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Head and Neck Squamous Cell Carcinoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Head and Neck Squamous Cell Carcinoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Head and Neck Squamous Cell Carcinoma Epidemiology, Segmented as –

  • Incident cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

  • Biomarker-specific incident Cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

  • Treatable Cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

  • Histology-specific incident Cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

  • Site-specific incident Cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

  • Stage-specific incident Cases of Head and Neck Squamous Cell Carcinoma (HNSCC) in the 7MM (2019–2032)

Head and Neck Squamous Cell Carcinoma (HNSCC) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Head and Neck Squamous Cell Carcinoma market or expected to be launched during the study period. The analysis covers the Head and Neck Squamous Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Head and Neck Squamous Cell Carcinoma drugs based on their sale and market share.

The report also covers the Head and Neck Squamous Cell Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Head and Neck Squamous Cell Carcinoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Head and Neck Squamous Cell Carcinoma Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

Head and Neck Squamous Cell Carcinoma (HNSCC) Therapeutics Analysis

Concurrent chemo-radiation therapy is the current standard of care for patients with locally advanced squamous cell carcinoma of the head and neck. The combination of radical surgery and radiation therapy has been used for several decades to treat patients with advanced head and neck cancers. Despite aggressive primary treatment, the majority of relapses that occur following head and neck cancer are within the head and neck. Loco-regional relapse accounts for nearly 80% of primary treatment failures. To further improve the treatment scenario, several major pharma and biotech giants are actively developing new therapies for Head and Neck Squamous Cell Carcinoma.

Head and Neck Squamous Cell Carcinoma (HNSCC) Companies Actively Working in the Therapeutics Market Include

  • Merck

  • Eli Lilly and Company

  • Bristol‑Myers Squibb

  • Sanofi-Aventis

  • Merck Sharp & Dohme Corp.

  • Sinocelltech Ltd.

  • GlaxoSmithKline

  • Hoffmann-La Roche

  • AstraZeneca

  • AVEO Pharmaceuticals, Inc.

And Many Others

Emerging and Marketed Head and Neck Squamous Cell Carcinoma (HNSCC) Therapies Covered in the Report Include:

  • Keytruda (Pembrolizumab): Merck

  • Erbitux (Cetuximab): Eli Lilly and Company

  • Opdivo (nivolumab): Bristol‑Myers Squibb

  • Taxotere (Docetaxel): Sanofi-Aventis

  • Lenvatinib (E7080/MK-7902): Merck Sharp & Dohme Corp.

  • SCT-I10A+Chemo: Sinocelltech Ltd.

  • GSK3359609: GlaxoSmithKline

  • Atezolizumab: Hoffmann-La Roche

  • MEDI4736: AstraZeneca

  • Ficlatuzumab: AVEO Pharmaceuticals, Inc.

And Many Others

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Head and Neck Squamous Cell Carcinoma Competitive Intelligence Analysis

4. Head and Neck Squamous Cell Carcinoma Market Overview at a Glance

5. Head and Neck Squamous Cell Carcinoma Disease Background and Overview

6. Head and Neck Squamous Cell Carcinoma Patient Journey

7. Head and Neck Squamous Cell Carcinoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Head and Neck Squamous Cell Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Head and Neck Squamous Cell Carcinoma Unmet Needs

10. Key Endpoints of Head and Neck Squamous Cell Carcinoma Treatment

11. Head and Neck Squamous Cell Carcinoma Marketed Therapies

12. Head and Neck Squamous Cell Carcinoma Emerging Drugs and Latest Therapeutic Advances

13. Head and Neck Squamous Cell Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Head and Neck Squamous Cell Carcinoma Market Outlook (In US, EU5, and Japan)

16. Head and Neck Squamous Cell Carcinoma Companies Active in the Market

17. Head and Neck Squamous Cell Carcinoma Access and Reimbursement Overview

18. KOL Views on the Head and Neck Squamous Cell Carcinoma Market

19. Head and Neck Squamous Cell Carcinoma Market Drivers

20. Head and Neck Squamous Cell Carcinoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Neuroleptic Malignant Syndrome Market

“Neuroleptic Malignant Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Neuroleptic Malignant Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Neuroleptic Malignant Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices